Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.12.7713

Methylation Profile of BRCA1, RASSF1A and ER in Vietnamese Women with Ovarian Cancer  

Lan, Vo Thi Thuong (Faculty of Biology, VNU University of Science)
Thuan, Ta Bich (Faculty of Biology, VNU University of Science)
Thu, Doan Minh (Faculty of Biology, VNU University of Science)
Uyen, Nguyen Quynh (Institute of Microbiology and Biotechnology, Vietnam National University)
Ha, Ngo Thi (Institute of Microbiology and Biotechnology, Vietnam National University)
To, Ta Van (Department of Cytology and Pathology, National Cancer Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.12, 2013 , pp. 7713-7718 More about this Journal
Abstract
DNA methylation is considered a promising biomarkers for diagnosis of cancer in general and of ovarian cancer in particular. In our study, we validated the accuracy of methylation specific polymerase chain reaction (MSP) to analyze the methylation pattern of BRCA1, RASSF1A and ER in 59 and 10 Vietnamese patients with epithelial ovarian cancer (EOC) and benign ovarian tumors, respectively. We found methylation of BRCA1, RASSF1A and ER in 11/59 (18.6%), 40/59 (67.8%) and 15/59 (25.4%) of EOC cases, while methylation of BRCA1 was only detected in 2/10 (20%) benign ovarian patients. Forty five out of the 59 EOCs (78%) demonstrated methylation at one or more genes. The methylation frequency of RASSF1A was significantly associated with EOC (p<0.0005). No significant association was observed between methylation status of these genes and the clinical and pathological parameters of tumors collected from Vietnamese women suffering from ovarian cancer.
Keywords
Breast cancer 1 (BRCA1); RAS-association domain family member 1 (RASSF1A); estrogen receptor ${\alpha}$ (ER);
Citations & Related Records
연도 인용수 순위
  • Reference
1 Barnholtz-Sloan JS, Schwartz AG, Qureshi F (2003). Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol, 189, 1120-7.   DOI   ScienceOn
2 Barton CA, Hacker NF, Clark SJ, Philippa M, O'Brien PM (2008). DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. Gynecol Oncol, 109, 129-9.   DOI   ScienceOn
3 BonDurant AE, Huang Z, Whitaker RS, et al (2011). Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol Oncol, 123, 581-7.   DOI   ScienceOn
4 Clark SJ, Harrison J, Paul CL, Frommer M (1994). High sensitivity mapping of methylated cytosines. Nucleic Acids Res, 22, 2990-7.   DOI   ScienceOn
5 de Caceres I, Battagli C, Esteller M, et al (2004). Tumor cellspecific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res, 64, 6476-1.   DOI   ScienceOn
6 Du XL, Sun CC, Milam MR, Bodurka DC, Fang S (2008). Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer, 18, 660-9.   DOI   ScienceOn
7 Esteller M, Silva JM, Dominguez G, et al (2000). Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst, 92, 564-70.   DOI   ScienceOn
8 Esteller M, Corn PG, Baylin SB, Herman JG (2001). A gene hypermethylation profile of human cancer. Cancer Res, 61, 3225-9.
9 Feng S, Rubbi L, Jacobsen SE, Pellegrini M (2011). Determining DNA methylation profiles using sequencing. Methods Mol Biol, 733, 223-8.   DOI   ScienceOn
10 Heichman KA, Warren JD (2012). DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med, 50, 1707-1.
11 Heyn H, Esteller M (2012). DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet, 13, 679-3.   DOI   ScienceOn
12 Houshdaran S, Hawley S, Palmer C, et al (2010). DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS ONE, 5, 9359.   DOI   ScienceOn
13 Lapidus RG, Nass SJ, Butash KA, et al (1998). Mapping of ER gene CpG island methylation by methylation-specific polymerase chain reaction. Cancer Res, 58, 2515-9.
14 Kristensen LS, Hansen L (2009). PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem, 55, 1471-3.   DOI   ScienceOn
15 Agathanggelou A, Honorio S, Macartney DP, et al (2001). Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20, 1509-8.   DOI   ScienceOn
16 Asadollahi R, Hyde AC, Zhong XY (2010). Epigenetics of ovarian cancer: From the lab to the clinic. Gynecol Oncol, 118, 81-7.   DOI   ScienceOn
17 Liu L, Yoon JH, Dammann R, Pfeifer GP (2002). Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogen, 21, 6835-1.   DOI   ScienceOn
18 Mann M, Cortez V, Vadlamudi RK (2011). Epigenetics of estrogen receptor signaling: Role in hormonal cancer progression and therapy. Cancers, 3, 1691-7.   DOI
19 Mehrotra J, Ganpat MM, Kanan Y, et al (2004). Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res, 10, 2052-7.   DOI   ScienceOn
20 Montavon C, Gloss BS, Warton K, et al (2012). Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol, 124, 582-8.   DOI   ScienceOn
21 Matoo AA, Khan H, Wani HA, et al (2013). RAS association domain isoform A gene (RASSF1A) hypermethylation in ovarian cancer patients of Kashmir Valley. J Pakistan Med Students, 3, 87-3.
22 Rathi A, Virmani AK, Schorge JO, et al (2002). Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res, 8, 3324-1.
23 Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N (2012). Methylation of tumor suppressor genes in ovarian cancer. Experimental and Therapeutic Medicine, 4, 1092-6.   DOI
24 Pan YM, Wu YZ, Shi YF, Zhu XQ (2010). Methylation of tumor suppressor gene RASSF1A and BRCA1 in primary epithelial ovarian cancer. Sci Res and Essays, 5, 3939-4.
25 Pathy NB, Hartman M, Yip CH, et al (2012). Ethnic differences in survival after breast cancer in South East Asia. PLoS ONE, 7, 30995.   DOI
26 Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-9.   DOI   ScienceOn
27 Teodoridis JM, Hall J, Marsh S, et al (2005). CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res, 65, 8961-7.   DOI   ScienceOn
28 Widschwendter M, Jones A, Teschendorff AE (2013). Epigenetics makes its mark on women-specific cancers-an opportunity to redefine oncological approaches? Gynecol Oncol, 128, 134-3.   DOI   ScienceOn
29 Wiencke JK (2004). Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer, 4, 79-4.   DOI   ScienceOn
30 Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA (2005). High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogen, 159, 114-2.   DOI   ScienceOn
31 Zhang Q, Hu G, Yang Q, et al (2013). A multiplex methylationspecific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol, 130, 132-9.   DOI   ScienceOn
32 Wiley A, Katsaros D, Chen H, et al (2006). Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovariantumors with low malignant potential. Cancer, 107, 299-8.   DOI   ScienceOn